- Home
- CATO vs MGX Comparison
CATO vs MGX Comparison
Compare CATO & MGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CATO
- MGX
- Stock Information
- Founded
- CATO 1946
- MGX 2018
- Country
- CATO United States
- MGX United States
- Employees
- CATO N/A
- MGX N/A
- Industry
- CATO Clothing/Shoe/Accessory Stores
- MGX
- Sector
- CATO Consumer Discretionary
- MGX
- Exchange
- CATO Nasdaq
- MGX NYSE
- Market Cap
- CATO 59.2M
- MGX 62.1M
- IPO Year
- CATO N/A
- MGX 2024
- Fundamental
- Price
- CATO $2.85
- MGX $1.52
- Analyst Decision
- CATO
- MGX Strong Buy
- Analyst Count
- CATO 0
- MGX 4
- Target Price
- CATO N/A
- MGX $13.00
- AVG Volume (30 Days)
- CATO 41.5K
- MGX 665.7K
- Earning Date
- CATO 08-21-2025
- MGX 08-13-2025
- Dividend Yield
- CATO 6.06%
- MGX N/A
- EPS Growth
- CATO N/A
- MGX N/A
- EPS
- CATO N/A
- MGX N/A
- Revenue
- CATO $642,949,000.00
- MGX $45,263,000.00
- Revenue This Year
- CATO N/A
- MGX N/A
- Revenue Next Year
- CATO N/A
- MGX $11.75
- P/E Ratio
- CATO N/A
- MGX N/A
- Revenue Growth
- CATO N/A
- MGX N/A
- 52 Week Low
- CATO $2.19
- MGX $1.23
- 52 Week High
- CATO $6.70
- MGX $5.50
- Technical
- Relative Strength Index (RSI)
- CATO 52.16
- MGX 47.41
- Support Level
- CATO $2.71
- MGX $1.46
- Resistance Level
- CATO $2.99
- MGX $1.66
- Average True Range (ATR)
- CATO 0.21
- MGX 0.13
- MACD
- CATO -0.02
- MGX 0.00
- Stochastic Oscillator
- CATO 25.64
- MGX 46.30
About CATO Cato Corporation (The)
The Cato Corp operates as a specialty retailer of fashion apparel and accessories in the southeastern United States. Its primary objective is to be the fashion specialty retailer for fashion and value in its markets. The company operates through the following business segments: Retail and Credit. The Retail segment which generates the majority of revenue offers fashion specialty stores. The Credit segment involves credit card services.
About MGX METAGENOMI INC
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.